» Articles » PMID: 15330907

Hepatocyte Apoptosis, Expression of Death Receptors, and Activation of NF-kappaB in the Liver of Nonalcoholic and Alcoholic Steatohepatitis Patients

Overview
Specialty Gastroenterology
Date 2004 Aug 28
PMID 15330907
Citations 139
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: The increasing incidence of nonalcoholic (NASH) and alcoholic steatohepatitis (ASH), associated with lack of effective treatment, has prompted intensive studies on disease pathogenesis. Apoptosis is recognized as common in liver injury and may also contribute to tissue inflammation, fibrogenesis, and development of cirrhosis. In this study, we identified mechanisms of apoptosis induction in human steatohepatitis, and evaluated potential associations between apoptosis, liver pathology, and clinical presentation in NASH and ASH.

Methods: Hepatocyte apoptosis was evaluated by the TUNEL assay in 20 patients with NASH (all ambulatory), 40 with ASH (20 ambulatory, 20 hospitalized), and 20 controls. Liver biopsies were also graded for inflammation and fibrosis. Immunohistochemistry was performed for death receptors (Fas and TNF-R1), activated caspase-3, NF-kappaB p65, antiapoptotic Bcl-2 protein, and uncoupling protein 2 (UCP-2).

Results: TUNEL-positive hepatocytes were markedly increased in NASH (p < 0.05) and ASH (p < 0.01). Similar results were obtained for activated caspase-3, confirming the occurrence of apoptosis. The Fas receptor was upregulated in ASH, especially in hospitalized patients (p < 0.01), whereas TNF-R1 was expressed both in NASH and ASH (p < 0.01). In addition, patients with ASH showed a remarkable expression of active NF-kappaB, as compared to NASH and controls (p < 0.01). Degrees of inflammation and fibrosis correlated with NF-kappaB p65 expression, which in turn coincided with apoptosis albeit Bcl-2 and UCP-2 expression.

Conclusions: Liver injury in NASH and ASH is associated with increased hepatocyte apoptosis mediated by death receptors. Further, apoptosis correlates with active NF-kappaB expression, and disease severity. This potential mechanistic link might provide multiple interesting targets for therapeutic intervention.

Citing Articles

Hypoxia-Inducible Factor-2α Promotes Liver Fibrosis by Inducing Hepatocellular Death.

Mooli R, Mukhi D, Watt M, Nagati V, Reed S, Gandhi N Int J Mol Sci. 2024; 25(23).

PMID: 39684823 PMC: 11642083. DOI: 10.3390/ijms252313114.


Chemogenomic Screening in a Patient-Derived 3D Fatty Liver Disease Model Reveals the CHRM1-TRPM8 Axis as a Novel Module for Targeted Intervention.

Youhanna S, Kemas A, Wright S, Zhong Y, Klumpp B, Klein K Adv Sci (Weinh). 2024; 12(3):e2407572.

PMID: 39605182 PMC: 11744578. DOI: 10.1002/advs.202407572.


Targeting ketone body metabolism to treat fatty liver disease.

Kwon S, Jeyaratnam R, Kim K J Pharm Pharm Sci. 2024; 27:13375.

PMID: 39403635 PMC: 11471530. DOI: 10.3389/jpps.2024.13375.


Targeting cell death in NAFLD: mechanisms and targeted therapies.

Xu H, Wan S, An Y, Wu Q, Xing Y, Deng C Cell Death Discov. 2024; 10(1):399.

PMID: 39244571 PMC: 11380694. DOI: 10.1038/s41420-024-02168-z.


Honey vesicle-like nanoparticles protect aged liver from non-alcoholic steatohepatitis.

Liu B, Nguyen P, Yu H, Li X, Wang H, Nguyen T Acta Pharm Sin B. 2024; 14(8):3661-3679.

PMID: 39220874 PMC: 11365403. DOI: 10.1016/j.apsb.2024.05.002.